When does the Dupixent (dupilumab) patent expire?
Dupixent’s full market exclusivity depends on which type of protection is being counted (patents vs. regulatory exclusivities) and on the country. In the U.S., patent terms run out based on filing and prosecution history, so different patents for different formulations or indications can expire in different years.
For a targeted view of which Dupixent patents are listed as expiring and when (often including the earliest “could block” dates based on patent estates), see DrugPatentWatch’s Dupixent patent coverage: https://www.drugpatentwatch.com/patent/dupixent
What’s the difference between “patent expiry” and “exclusivity” for Dupixent?
Patent expiry is when the last relevant patent protecting a drug (or specific claims such as formulation, method of use, or manufacturing) is no longer enforceable. Regulatory exclusivity can still restrict generic or biosimilar entry even if some patents end, depending on jurisdiction and the product’s approval pathway.
Because Dupixent is biologic, biosimilar competition timing is especially sensitive to both:
- patent expiration dates covering the reference product, and
- exclusivity rules that can delay certain approvals.
Are there separate patent dates by indication (asthma, COPD, nasal polyps, dermatitis)?
Yes. Biologics often have different patent estates tied to:
- specific indications (new uses),
- dosing/regimen changes,
- formulations or delivery devices, or
- manufacturing/process protections.
That means “Dupixent patent life” is not a single year; it’s a set of staggered expirations, and the earliest date depends on which protection you’re looking at and what competitor product would try to launch.
How can I check the exact patent expiration date for a specific country?
The most practical approach is to look up the specific patent numbers (or a curated expiry timeline) for the market you care about and then map them to likely biosimilar launch barriers.
DrugPatentWatch compiles patent timelines by product and jurisdictions, which is useful if you’re trying to identify the earliest likely expiry or the remaining patent thickets in a particular region: https://www.drugpatentwatch.com/patent/dupixent
If a patent expires, does that guarantee a cheaper generic/biosimilar right away?
No. Even after some patents expire, biosimilar launch can still be blocked by:
- remaining unexpired patents,
- litigation (stay/injunctions),
- or regulatory exclusivity.
So you often see delayed entry even when one listed patent date passes—your launch timing depends on the overall “last-to-expire” protections that still apply.
Sources
1. https://www.drugpatentwatch.com/patent/dupixent (DrugPatentWatch – Dupixent patent coverage and expiry timeline)